Mode
Text Size
Log in / Sign up
N/A Completed N=407

RUSSE / Russian Spiriva® Safety & Efficacy Study

Source: ClinicalTrials.gov NCT00613574 ↗
Enrolled (actual)
407
Serious AEs
0.5%
Results posted
Jan 2010
Primary outcomePrimary: Change From Baseline in Post-dose Forced Expiratory Volume in 1 Second After 8 Weeks — 0.29 liters

Summary

At the moment, there is hardly any structured safety and efficacy data collection on Tiotropium in Russia. Therefore, the objective of this observational study is to collect and evaluate data on bronchodilator efficacy and safety of Spiriva® (18 µg tiotropium inhalation capsules) delivered by HandiHaler®, in a national sample of Russian patients with varying severities of chronic obstructive pulmonary disease (COPD) in a real life setting over the 8 weeks.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in Post-dose Forced Expiratory Volume in 1 Second After 8 Weeks
0.29 —
SECONDARY
Change From Baseline for Forced Vital Capacity After 8 Weeks
0.31 —
SECONDARY
Change From Baseline for Inspiratory Capacity (*Only Selected Sites) After 8 Weeks
0.18 —
SECONDARY
Patients Global Clinical Assessment of Efficacy at Final Visit by Severity, Full Analysis Set (FAS)
141; 198; 60; 2 —
SECONDARY
Patients Global Clinical Assessment of Tolerability at Final Visit by Severity, FAS
246; 139; 16; 0 —
SECONDARY
Physicians Global Clinical Assessment of Effect at Final Visit by Severity, FAS
159; 195; 45; 2 —
SECONDARY
Physicians Global Clinical Assessment of Tolerability at Final Visit by Severity, FAS
246; 144; 11; 0 —

Eligibility Criteria

Inclusion Criteria

  • 40 years and older male and female ambulatory outpatients being seen in a participating physicians office for routine care
  • Patients not previously treated with the Tiotropium
  • Patients with clinical diagnosis of all stages of Chronic Obstructive Pulmonary Disease according to the current National Guidelines / 2004
  • Current smokers or ex-smokers with a smoking history of >=10 pack years

Exclusion Criteria

  • Uncooperative patients as judged by the physician,
  • Patients that have any condition which, according to the participating physicians opinion, might decrease the chance of obtaining satisfactory data to achieve the objectives of the observation,
  • Patients with history of known preexisting or concomitant non-obstructive lung disease (e.g., sarcoidosis, tuberculosis, lung cancer),
  • Patients currently enrolled in another clinical trial which requires a change in medication for their respiratory problems,
  • Patients with any conditions listed in special precautions, drug interactions, and contraindication of Spiriva®'s Russian package insert, such as:
  • Patients with known narrow-angle glaucoma,
  • Patients with known symptomatic prostatic hypertrophy or bladder neck obstruction,
  • Patient with known moderate to severe renal impairment (creatinine clearance less than 50 ml/min),
  • Patients with a history of hypersensitivity to atropine or its derivatives, e.g. ipratropium or oxitropium or to any component of this product,
  • Pregnant or nursing women.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00613574). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search